| Symbol | BLLN |
|---|---|
| Name | BILLIONTOONE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 1035 OBRIEN DRIVE, MENLO PARK, California, 94025, United States |
| Telephone | +1 650 460-2551 |
| Fax | — |
| — | |
| Website | billiontoone.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002070849 |
| Description | BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible - detecting and precisely quantifying genetic targets with single-molecule sensitivity. This superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine. We believe our novel smNGS platform technologies, combined with our AI-enhanced integrated workflow, allow us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy. Additional info from NASDAQ: |
Johnson Nancy JoAnn 🔴 sold 14.2K shares of BillionToOne, Inc. (BLLN) at $129.78 ($1.8M) Transaction Date: Jul 16, 2026 | Filing ID: 000044
Read more📋 Johnson Nancy JoAnn (Officer) plans to sell 14K shares of BillionToOne, Inc. (at $128.29 each, total $1.8M) Filed: Jul 16, 2026 | ID: 005259
Read moreten Bosch John Roderick 🔴 sold 4.3K shares of BillionToOne, Inc. (BLLN) at $125.46 Transaction Date: Jul 13, 2026 | Filing ID: 000006
Read moreDirector Tsao David 🟡 adjusted position in 20.0K shares (2 derivative) of BillionToOne, Inc. (BLLN) at $126.90 ($2.6M) Transaction Date: Jul 13, 2026 | Filing ID: 000004
Read moreBillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
Read moreJohnson Nancy JoAnn 🔴 sold 801 shares of BillionToOne, Inc. (BLLN) at $124.91 Transaction Date: Jul 01, 2026 | Filing ID: 000002
Read more📋 Atay Oguzhan (Member of immediate family of any of the foregoing) plans to sell 12K shares of BillionToOne, Inc. (at $122.05 each, total $1.5M) Filed: Jul 06, 2026 | ID: 005118
Read more📋 Atay Oguzhan (Officer) plans to sell 26K shares of BillionToOne, Inc. (at $120.00 each, total $3.1M) Filed: Jul 06, 2026 | ID: 005115
Read more📋 Atay Oguzhan (Officer) plans to sell 2K shares of BillionToOne, Inc. (at $120.00 each, total $300K) Filed: Jul 06, 2026 | ID: 005112
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07643896 | The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Condi… | — | Pregnant Individuals | Recruiting | 2026-01-10 | 2028-06-01 | ClinicalTrials.gov |
| NCT07096362 | Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancre… | Phase2 | Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | 2025-09-09 | 2030-09-30 | ClinicalTrials.gov |
| NCT05733689 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | Phase1 | Gastroesophageal Adenocarcinoma | Recruiting | 2025-06-27 | 2027-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Nab Paclitaxel | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Leucovorin | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Oxaliplatin | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| 5-Fluorouracil | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Trastuzumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| Durvalumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PEMBROLIZUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| NIVOLUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| DOCETAXEL and IRINOTECAN (alone or combined) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PACLITAXEL with or without CARBOPLATIN | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRINOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRI | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FLOT | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| Trastuzumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| Durvalumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PEMBROLIZUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| NIVOLUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| DOCETAXEL and IRINOTECAN (alone or combined) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PACLITAXEL with or without CARBOPLATIN | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRINOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRI | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FLOT | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |